Evidence map›Paper›PMID 26594303›Full record

ReviewThe World Allergy Organization journal2015

Allergen Immunotherapy (AIT): a prototype of Precision Medicine.

G W Canonica, C Bachert, P Hellings, D Ryan, E Valovirta, M Wickman, O De Beaumont, J Bousquet

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The World Allergy Organization journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Treatment of Allergies to Fur Animals.International journal of molecular sciences · 2024
    Review
  13. Prenatal Factors in the Development of Allergic Diseases.International journal of molecular sciences · 2024
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Allergen immunotherapy in China.Frontiers in allergy · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

G W CanonicaAllergy and Respiratory Diseases -DIMI Department of Internal Medicine, University of Genova, IRCCS AOU San Martino, Genova, 16132 Italy.
C BachertUpper Airways Research Laboratory, ENT-Department, University of Ghent, 9000 Ghent, Belgium.
P HellingsDepartment of Otorhinolaryngology, University of Leuven, Leuven, Belgium ; Department of Otorhinolaryngology, University of Amsterdam, Amsterdam, The Netherlands.
D RyanAllergy and Respiratory Research Group, Centre for Population Health Sciences, University of Edinburgh, Edinburgh, EH8 9AG UK.
E ValovirtaDepartment of Pulmonary and Allergic Diseases and Clinical Allergology, University of Turku, Turku, Finland.
M WickmanDepartment of Environmental Medecine, Karolinska Institutet, Sachs' Children's Hospital, Stockholm, Sweden.
O De BeaumontStallergenes, Antony, France.
J BousquetUniversity hospital, Montpellier, MACVIA-LR, Contre les Maladies Chronique spour un Vieillissement Actif en Languedoc Roussilon, European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France ; INSERM, VIMA : Ageing and chronic diseases Epidemiological and public health approaches, U1168 Paris, France ; UVSQ, UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Versailles, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Precision medicine is a medical model aiming to deliver customised healthcare - with medical decisions, practices, and/or products tailored to the individual patient informed but not directed by guidelines. Allergen immunotherapy has unique immunological rationale, since the approach is tailored to the specific IgE spectrum of an individual and modifies the natural course of the disease as it has a persistent efficacy after completion of treatment. In this perspective Allergen Immunotherapy - AIT has to be presently considered a prototype of Precision Medicine. Precise information and biomarkers provided by systems medicine and network medicine will address the discovery of Allergen immunotherapy biomarkers for (i) identification of the causes, (ii) stratification of eligible patients for AIT and (iii) the assessment of AIT efficacy. This area of medical technology is evolving rapidly and, compelemented by e-health, will change the way we practice medicine. It will help to monitor patients' disease control and data for (i) patient stratification, (ii) clinical trials, (iii) monitoring the efficacy and safety of targeted therapies which are critical for reaching an appropriate reimbursement. Biomarkers associated with e-health combined with a clinical decision support system (CDSS) will change the scope of Allergen immunotherapy. The cost/effectiveness of Allergen immunotherapy is a key issue for successful implementation. It should include the long-term benefits in the pharmaco-economic evaluation, since no other allergy treatment has this specific characteristic. AIT is the prototype of current and future precision medicine.

Indexed as

AITAllergen immunotherapyAllergyPersonalized medicinePrecision medicine

Identifiers

PMID26594303
PMCPMC4640346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.